Favipiravir-resistant influenza A virus shows potential for transmission

Favipiravir is a nucleoside analogue which has been licensed to treat influenza in the event of a new pandemic. We previously described a favipiravir resistant influenza A virus generated by in vitro passage in presence of drug with two mutations: K229R in PB1, which conferred resistance at a cost t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS Pathog
Autors principals: Goldhill, Daniel H., Yan, Ada, Frise, Rebecca, Zhou, Jie, Shelley, Jennifer, Gallego Cortés, Ana, Miah, Shahjahan, Akinbami, Omolola, Galiano, Monica, Zambon, Maria, Lackenby, Angie, Barclay, Wendy S.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2021
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8195362/
https://ncbi.nlm.nih.gov/pubmed/34061908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.ppat.1008937
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars